Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(2.61) per share which missed the analyst consensus estimate of $(2.10) by 24.29 percent. This is a 8.75 percent decrease over losses of $(2.40) per share from the same period last year.
Lanvin Group Announces Record 52% Pro Forma Revenue Growth in 2021 to €339 million and Filing of Registration Statement on F-4
Strong Momentum and Positive 2022 Outlook Ahead of Proposed NYSE Listing
52% pro forma global revenue growth driven by successful implementation of global growth strategy and acquisition of Sergio
